Breaking Finance News

NanoString Technologies (NDAQ:NSTG) has been downgraded from Buy to Neutral in a report by Janney Capital today.

Janney Capital has downgraded NanoString Technologies (NDAQ:NSTG) from Buy to Neutral in a report released on Thursday October 12, 2017.

Previously on 4/21/2017, Morgan Stanley reported about NanoString Technologies (NDAQ:NSTG) raised the target price from $19.00 to $20.00 that suggested an upside of 0.15%.

Boasting a price of $10.49, NanoString Technologies (NDAQ:NSTG) traded -37.04% lower on the day. With the last stock price close down -40.71% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. NSTG has recorded a 50-day moving average of $15.72 and a 200-day moving average of $16.63. 745,970 shares of NSTG traded, up from an avg. volume of 170,649

Recent Performance Chart

NanoString Technologies (NDAQ:NSTG)

NanoString Technologies has a 52 week low of $9.81 and a one year high of $23.45 NSTG’s market cap is currently $0.

In addition to Janney Capital reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $19.20 with 3 firms rating the stock a strong buy, 3 firms rating the stock a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

More About NanoString Technologies (NDAQ:NSTG)

NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company's nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.